Introduction
============

Ovarian cancer (OC) represents one of the leading causes of cancer mortality, exhibiting a five-year survival rate of 44%.[@b1-cin-14-2015-113] The serous ovarian cancer (SOC) high-grade subtype is one of the most aggressive and metastatic forms of cancer.[@b2-cin-14-2015-113] A number of previous studies focused on identifying the major genetic events that characterize and drive OC.[@b3-cin-14-2015-113]--[@b5-cin-14-2015-113] *TP53* mutations, *CCNE1* amplifications, and *BRCA1/2* (and associated homologous recombination pathway) aberrations along with a few highly recurrent mutations or pathways have been observed to be associated with tumorigenesis in SOC.[@b2-cin-14-2015-113],[@b6-cin-14-2015-113]

The need to better characterize the molecular genetics driving and accelerating OC have paved the way for large-scale studies with big cohorts profiled by a number of different omics technologies. One such study, The Cancer Genome Atlas (TCGA), profiled 572 different SOC tumors with RNA-Seq, Gene Expression Microarray, SNP 6.0 (copy number), and a number of other different platforms in addition to capturing clinical endpoints.[@b6-cin-14-2015-113] A breakdown of the key characteristics of the SOC study cohort is shown in [Table 1](#t1-cin-14-2015-113){ref-type="table"}. The large sample size is especially important as cancer is recognized as being a heterogeneous disease, and thus finding drivers or genes playing a role in aggressiveness in a fraction of tumors is severely limited by small cohorts.

The goal of this analysis was to determine genes whose expression and copy number changes associated with survival in SOC, even if the relative subset of patients was a small percentage. To this end, we initially used the TCGA SOC data to determine relevant survival-associated genes and then confirmed our discoveries with additional similar datasets available in the public domain. Results point to copy number amplification (CNA) and elevated gene expression levels of *FXYD5* to be markers of poor survival in SOC.

Materials and Methods
=====================

Data acquisition
----------------

TCGA SOC Affymetrix Human Genome U133A microarray gene expression data were obtained from TCGA Data Portal by using the Data Matrix method (<https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp>). TCGA copy number data were collected with the help of the Cancer Genomics Data Server R (cgdsr) package (version 1.1.30) in R (version 2.15.3). Using a tool developed at MD Anderson Cancer Center, it was verified that the expression and copy number data did not suffer from significant batch effects (<http://bioinformatics.mdanderson.org/tcgambatch/>). The Vienna OC dataset (GSE49997), profiled on ABI Microarray version 2, was acquired for validation from the Gene Expression Omnibus (GEO) using the GEOquery (version 2.13) package in R. Also for further validation, the Mass General Hospital (MGH)'s high-grade SOC expression dataset (GSE18520), profiled on the Affymetrix Human Genome U133 Plus 2.0 Array, was selected from NCBI's Entrez GEO DataSets database.

Statistical analyses
--------------------

Survival analysis was performed on TCGA's copy number and expression data using the Mantel--Haenszel log-rank test and Cox proportional hazard regression in the Survival package (version 2.37--7) of R. As copy number and expression values are continuous variables, we incorporated a scanning approach to the Kaplan--Meier method by moving samples between the two groups to define the best *P*-value as the breakpoint or separation point R2: Genomics Analysis and Visualization Platform (<http://r2.amc.nl>). For instance, for a particular gene, the expression values were sorted. Upon sorting, the bottom 5% were assigned to group 1 and the top 95% were assigned to group 2. This step serves to convert this continuous variable into a binary variable for subsequent survival analysis. At this point, the log-rank test was run on the two groups (group 1 and group 2), and a *P*-value was calculated. In the subsequent step, the smallest sample from group 2 was transferred to group 1 and the log-rank test was run again. This moving of samples iteratively continued until group 1 encapsulated the bottom 95% of values and group 2 held the top 5% of values. The lowest *P*-value was then chosen as the optimal breakpoint of the two groups and reported. A Benjamini--Hochberg correction was performed on all the *P*-values generated from this scanning approach to reflect the presence of multiple hypotheses testing. Consider, for example, 100 samples of data, one would end up running 91 different log-rank tests for a given gene using this approach. The multiple hypothesis problem grows linearly with the sample size. In the end, both the original and corrected *P*-values were returned at the optimal breakpoint (lowest *P*-value) for each gene. At this point, this same exercise was performed using the copy number data for each gene. Although, many times, studies bin copy number data into amplified, deleted, and neutral, this may not accurately reflect the clonal nature of the cancer. Some proportion of the cells in a sample dataset may have high gains, whereas others might have "neutral" copy numbers. The eventual copy number reported then actually represents an average of the clonal populations in the sample, thus hiding a subset with highly amplified copy number. Hence, the rationale for us to treat copy number as a continuous value and use the aforementioned Kaplan--scanning approach. At the end of this step, we had statistics on how the copy number and expression levels of all genes profiled, correlated with survival. Data are not available yet in the literature to track how the copy number profiles for genes change for a patient reflecting how clonal population percentages oscillate.

For our candidate hypothesis selection step, we chose genes having an adjusted *P*-value \< 0.05 in both the expression and copy number analysis, ensuring these genes had correlated expression and copy number data. Visualization of results was performed using ggplot2 (version 0.9.3.1) and VennDiagram (version 1.6.5) packages in R. The procedure was employed for both the discovery (TCGA) and validation datasets (GEO).

Results
=======

The Kaplan--Meier scan on the copy number identified 128 genes, as associated with survival, meeting the Benjamini--Hochberg corrected *P*-value \< 0.05 cutoff criteria. A similar analysis using the expression data yielded 158 genes. The intersection of these two lists ([Fig. 1A](#f1-cin-14-2015-113){ref-type="fig"}) subsumed four genes ([Supplementary Table 1](#s1-cin-14-2015-113){ref-type="supplementary-material"}). We performed correlation of expression and copy number for each of these genes, as illustrated in [Figure 1B](#f1-cin-14-2015-113){ref-type="fig"} for *FXYD5*, and all genes had copy number changes in line with expression changes.

A literature search on the association of the four candidate genes with aggressive forms of cancers pointed to *FXYD5* as a potential driver of metastasis in SOC as shown in [Table 2](#t2-cin-14-2015-113){ref-type="table"}. This gene sits within the 19q13 locus, documented to have CNA in SOC.[@b7-cin-14-2015-113] *FXYD5* codes dysadherin, a cancer-linked cell membrane protein known to upregulate chemokine production and downregulate E-cadherin.[@b8-cin-14-2015-113] FXYD5 expression has similarly been shown to induce vimentin expression in murine airway epithelial cells.[@b9-cin-14-2015-113] Both increased vimentin expression and decreased E-cadherin are causally associated with epithelial--mesenchymal transition, linking FXYD5 with EMT.

We wanted to investigate further whether *FXYD5* was a marker of aggressive SOC, given its known role in cancer. [Figures 1C](#f1-cin-14-2015-113){ref-type="fig"} and [1D](#f1-cin-14-2015-113){ref-type="fig"} show the results of the Kaplan--Meier survival analysis using gene expression and copy number, respectively. It is clear from the figures that CNA and elevated expression of *FXYD5* independently constitute an effective marker for poor survival. Additionally, [Figure 1B](#f1-cin-14-2015-113){ref-type="fig"} shows elevated expression of *FXYD5* in the *FXYD5* amplified group (\>six copies). Comparing the expression levels of *FXYD5* in the two groups using the Kolmogorov--Smirnov test, we found a statistically significant difference (*P* = 0.00014), thus confirming a positive correlation between expression and copy number for *FXYD5*. A more detailed scatter-plot of *FXYD5* copy number levels versus expression levels is included in [Supplementary Figure 1](#s1-cin-14-2015-113){ref-type="supplementary-material"}.

To further confirm our discovery of *FXYD5* as a marker for aggressive OC, we performed survival analysis in another OC microarray study (GSE49997), which used a different platform (ABI Microarray version 2) on 204 epithelial OC samples.[@b10-cin-14-2015-113] In this dataset, high expression of *FXYD5* was again associated with poor outcome at the appropriate significance level (*P* \< 0.05) in the SOC samples ([Fig. 2A](#f2-cin-14-2015-113){ref-type="fig"}). Furthermore, using the MGH gene expression microarray dataset (GSE18520), which profiled 53 samples on the Affymetrix Human Genome U133 Plus 2.0 Array, we found again that high expression of *FXYD5* was associated with poor survival (*P* \< 0.005, [Fig. 2B](#f2-cin-14-2015-113){ref-type="fig"}).[@b11-cin-14-2015-113] Note that none of the other three genes, *PSMC4*, *ZFP36*, and *POLR2I*, had a significant association with survival in both of these validation data sets, thus substantiating our decision to pursue *FXYD5*.

To validate the clinical utility of FXYD5 expression in SOC, we also performed a multivariate analysis on our original TCGA dataset taking into account race, lymphatic invasion, tumor residual disease, and stage. Age (originally included) was taken out by stratification because it was not a constant hazard, and thus violated certain assumptions of the analysis. *FXYD5* expression was still significantly associated with poor survival with a hazard ratio of 1.16 and *P*-value of 0.02 ([Supplementary Table 2](#s1-cin-14-2015-113){ref-type="supplementary-material"}). A similar multivariate analysis was done using the aforementioned clinical annotation and *FXYD5* copy number. Here again, we found a hazard ratio of 1.16 and a slightly higher *P*-value of 0.06 ([Supplementary Table 3](#s1-cin-14-2015-113){ref-type="supplementary-material"}).

Next, we examined the Cancer Cell Line Encyclopedia (CCLE) and found that in fact *FXYD5* is amplified, compared to other cancer lines, in NIH:OVCAR-3 (second line in figure), a cell line established from a highly progressive ovarian adenocarcinoma ([Fig. 2C](#f2-cin-14-2015-113){ref-type="fig"}).[@b12-cin-14-2015-113] Another OC cell line JHOS4-ovary, which is known for its slow growth, was among the lines of minimal *FXYD5* copy number. The findings on cell lines not only strengthens the case of *FXYD5* as a marker for poor diagnosis in OC but also provides an avenue for further testing with appropriate cell culture models.

Finally, it is well known that transcript levels do not always correlate with protein expression, thus having *FXYD5* protein levels would be ideal. Unfortunately, there is no *FXYD5* proteomics data in TCGA OC data set. However, eight of 11 OC samples were found to have either a medium or high degree of *FXYD5* antibody (HPA010817) staining localized to the cytoplasm or membrane based on data from the human protein atlas.[@b13-cin-14-2015-113]

Discussion
==========

Survival analysis on SOC samples presented by TCGA identified *FXYD5* as a potential marker of metastasis in a subset of patients both in copy number and expression. We have checked the validity of our discovery by employing the same survival analysis on two other open-access microarray datasets. The results for the three different datasets were consistent and pointed to *FXYD5* as a poor diagnosis marker for OC. None of the other genes in our list of four that exhibited elevated *FXYD5* in poor outcome samples were as efficient in identifying poor prognosis as *FXYD5*.

Dysadherin, which is coded by *FXYD5*, functions in chemokine production central to growth, survival, and migration of cancer cells from the primary tumor. Additionally, as it downregulates E-cadherin and upregulates vimentin, it may serve to push the cell from epithelial to mesenchymal state, implicating this gene in metastasis. Moreover, recent studies identified dysadherin as an activator of *AKT1* and a driver of the oncogenic *PIK3CA* pathway.[@b14-cin-14-2015-113] To the best of our knowledge, dysadherin has not been linked to OC until this study. As in [Table 2](#t2-cin-14-2015-113){ref-type="table"}, it has been linked, however, to a large number of cancers as a marker for poor diagnosis. Our finding that *FXYD5* is also a marker for poor survival in OC will provide a new light on metastasis patterns involving breast, cervical, and ovarian cancers.

Cancer driver genes have been annotated in the literature using different definitions based on mutational patterns.[@b15-cin-14-2015-113] A recent study by Tamborero et al identified genes deemed driver by four different methods, and *FXYD5* is not in the list of intersections of driver genes identified in this study.[@b16-cin-14-2015-113] The small intersection between the different methods attests, however, to challenges for algorithmic identification of drivers of cancer. We think of *FXYD5* not as an initiator of cancer but as a potential driver for metastasis of OC based on the finding that poor prognosis is linked to both elevated CNA and transcript expression.[@b24-cin-14-2015-113]

Since effective antibodies exist against dysadherin, fluorescence labeling of tissue arrays will identify whether this protein is a differentiating factor for poor prognosis in a clinical setting. In another set of experiments, gene silencing and rescue experiments could transform *FXYD5* from a marker for poor diagnosis to metastasis driver, with causality and conclusion. If, in fact, the oncogenic potential of dysadherin is mediated via *AKT1* and the *PIK3CA* pathway, then the emerging drug therapies in clinical trials and on the market targeting this pathway may be candidate treatment options for aggressive OC.[@b17-cin-14-2015-113] Additionally, if *FXYD5* is indeed simply a marker for metastasis, then aggressive disease modern therapeutic modalities such as antibody-drug conjugate or chimeric antigen receptor could be employed to target cancer cells with suitable expression of this gene. Indeed, a search in google patents reveals a patent (US 20110064752 A1) for a biologic Extracellular targeted drug conjugates (EDC) targeting *FXYD5* with purported use in various cancers further strengthening the case to interrogate this target further in OC.
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**Supplementary Figure 1.** *FXYD5* copy number versus mRNA expression scatter-plot.

**Supplementary Table 1.** Genes identified from SOC TCGA analysis as being associated with poor prognosis.

**Supplementary Table 2.** Multivariate analysis (Cox regression) with FXYD5 mRNA expression and other prognostic factors.

**Supplementary Table 3.** Multivariate analysis (Cox regression) with FXYD5 copy number and other prognostic factors.
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![*FXYD5* is a marker for aggressive OC, as determined by the TCGA dataset. Intersection of gene sets with elevated gene expression and elevated copy number (**A**), Box plot of showing expression versus amplification for *FXYD5* (**B**), and Kaplan--Meier survival curves showing survival based on *FXYD5* expression and copy number data, respectively (**C, D**).](cin-14-2015-113f1){#f1-cin-14-2015-113}
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###### 

SOC TCGA study cohort information.

  FACTOR                                GROUP                                       VALUE
  ------------------------------------- ------------------------------------------- -------
  Age at initial pathologic diagnosis   Min.                                        26
                                        1st Qu.                                     51
                                        Median                                      59
                                        Mean                                        59.68
                                        3rd Qu.                                     68
                                        Max.                                        89
  Anatomic neoplasm subdivision         Not available                               32
                                        Bilateral                                   396
                                        Left                                        79
                                        Right                                       66
  Clinical stage                        Stage IIIC                                  407
                                        Stage IV                                    86
                                        Stage IIIB                                  24
                                        Stage IIC                                   20
                                        Stage IC                                    10
                                        Stage IIIA                                  8
                                        Other                                       18
  Neoplasm histologic grade             Not available                               3
                                        G1                                          6
                                        G2                                          69
                                        G3                                          484
                                        G4                                          1
                                        GB                                          1
                                        GX                                          9
  Race                                  Not available                               32
                                        American indian or alaska native            3
                                        Asian                                       19
                                        Black or african american                   24
                                        Native hawaiian or other pacific islander   1
                                        White                                       494
  Tumor residual disease                Not available                               61
                                        \>20 mm                                     105
                                        1--10 mm                                    253
                                        11--20 mm                                   37
                                        No macroscopic disease                      117
  Vital status                          Not available                               3
                                        Alive                                       272
                                        Dead                                        298

###### 

Literature references of *FXYD5* association with cancer.

  CANCER                               JOURNAL                                REF \#                   ARTICLE
  ------------------------------------ -------------------------------------- ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Thyroid neoplasias                   J Clin Endocrinol Metab.               [@b18-cin-14-2015-113]   Colamaio et al. 2012: Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene.
  Breast carcinomas                    Cancer Sci.                            [@b19-cin-14-2015-113]   Lee et al. 2012: Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation.
  Renal cell carcinoma                 Int J Cancer.                          [@b20-cin-14-2015-113]   Schuler et al. 2012: Osteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells.
  Fibrous sinovial sarcoma             Arch Pathol Lab Med.                   [@b21-cin-14-2015-113]   Subramaniam et al. 2011: Immunohistochemical study of correlation between histologic subtype and expression of epithelial-mesenchymal transition-related proteins in synovial sarcomas.
  Hepatocellular carcinoma             J Hepatol.                             [@b22-cin-14-2015-113]   Park et al. 2011: Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells.
  Gastric carcinomas                   Hum Pathol.                            [@b23-cin-14-2015-113]   Maehata et al. 2011: Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion.
  Lung carcinomas                      Histol Histopathol.                    [@b32-cin-14-2015-113]   Mitselou et al. 2010: Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
  GIST                                 Pathol Res Pract.                      [@b33-cin-14-2015-113]   Liang et al. 2009: Dysadherin expression in gastrointestinal stromal tumors (GISTs).
  Colorectal carcinomas                Oncology                               [@b25-cin-14-2015-113]   Ochiai et al. 2008: A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases.
  Colorectal cancer                    Virchows Arch.                         [@b26-cin-14-2015-113]   Batistatou et al. 2006: Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma
  Head and neck squamous carcinoma     Am. J. Surg. Pathol.                   [@b27-cin-14-2015-113]   Kyzas et al. 2006: Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance
  Testicular tumors                    Br J. Cancer                           [@b28-cin-14-2015-113]   Batistatou et al. 2005: Involvement of dysadherin and E-cadherin in the development of testicular tumours
  Non-small cell lung cancer           J. Thorac. Cardiovasc. Surg            [@b29-cin-14-2015-113]   Tamura et al. 2005: Prognostic significance of dysadherin expression in patients with non-small cell lung cancer
  Cutaneous malignant melanoma         Cancer                                 [@b30-cin-14-2015-113]   Nishizawa et al. 2005: Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients
  Cervical squamous cell carcinoma     Pathol. Oncol. Res.                    [@b31-cin-14-2015-113]   Wu et al. 2004: Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
  Tongue cancer                        Appl. Immunohistochem. Mol. Morphol.   [@b33-cin-14-2015-113]   Nakanishi et al. 2004: Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases
  Esophageal squamous cell carcinoma   Oncology                               [@b34-cin-14-2015-113]   Shimada et al. 2004: Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma
  Gastric cancer                       Clin. Cancer Res.                      [@b35-cin-14-2015-113]   Shimada et al. 2004: Clinical significance of dysadherin expression in gastric cancer patients
  Thyroid cancer                       J. Clin. Endocrinol. Metab.            [@b36-cin-14-2015-113]   Sato et al. 2003: Dysadherin: expression and clinical significance in thyroid carcinoma
  Pancreatic ductal adenocarcinoma     J. Clin. Oncol.                        ^37^                     Shimamura et al. 2003: Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression
  Breast cancer (stage II)             Proc. Natl. Acad Sci.                  ^38^                     Ino et al. 2002: Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis
